trim33 Antibody

What is TRIM33 and why is it important in cellular research?

TRIM33 (Tripartite motif containing 33), also known as TIF1G, ECTO, PTC7, RFG7, or E3 ubiquitin-protein ligase TRIM33, is a multifunctional protein of approximately 122.5 kDa . It plays critical roles in:

• TGF-β/BMP signaling pathway regulation through SMAD4 monoubiquitination

• Transcriptional repression

• Cell proliferation control

• Hematopoietic differentiation

• Innate immunity via the NLRP3 inflammasome

• Development of pre-cardiogenic mesoderm

The importance of TRIM33 in research stems from its involvement in crucial biological processes including cellular differentiation, immune response, and cancer progression .

How do I select the appropriate TRIM33 antibody for my research?

When selecting a TRIM33 antibody, consider these research-critical factors:

For reproducible results, validate antibody specificity in your experimental system using positive controls and TRIM33 knockdown/knockout samples .

What are the optimal conditions for Western blot detection of TRIM33?

For optimal Western blot detection of TRIM33:

Sample preparation:

• Use nuclear extracts for enriched detection as TRIM33 localizes primarily to the nucleus

• Include protease inhibitors to prevent degradation

Electrophoresis and transfer parameters:

• Expected molecular weight: 122.5 kDa (theoretical), but typically observed at 140-150 kDa

• Use 8% SDS-PAGE gels to effectively resolve this high molecular weight protein

Antibody dilutions and detection:

• Primary antibody working dilutions: 1:500-1:1000

• Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG (1:5000)

• Enhanced chemiluminescence detection with 1-5 minute exposure

Controls:

• COLO 320, MCF-7, or PC-3 cells as positive controls

• TRIM33 knockdown/knockout samples as negative controls

How can I effectively use TRIM33 antibodies in immunofluorescence applications?

For successful immunofluorescence with TRIM33 antibodies:

Sample preparation:

• Fix cells with 4% paraformaldehyde (10 minutes, room temperature)

• Permeabilize with 0.2% Triton X-100 (5 minutes)

• Block with 5% normal serum from secondary antibody host (1 hour)

Staining protocol:

• Primary antibody: Incubate at 1:50-1:200 dilution (overnight, 4°C)

• Secondary antibody: Fluorophore-conjugated anti-IgG (1:500, 1 hour, room temperature)

• Counterstain nuclei with DAPI (TRIM33 exhibits predominantly nuclear localization)

Critical considerations:

• Include no-primary antibody control

• Use confocal microscopy for co-localization studies with nuclear markers

• When studying TRIM33's dynamic localization, note that nuclear translocation occurs 48 hours after antigen stimulation in T cells

What are the recommended protocols for immunoprecipitation of TRIM33?

For effective TRIM33 immunoprecipitation:

Lysis buffer composition:

• 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40

• Add 1 mM EDTA, protease and phosphatase inhibitors

• For protein interaction studies, consider gentler lysis conditions with 0.3% NP-40

Immunoprecipitation protocol:

• Pre-clear lysate (500-1000 μg) with Protein A/G beads (1 hour, 4°C)

• Incubate cleared lysate with TRIM33 antibody (1:100 dilution; 5 μg)

• Add Protein A/G beads and incubate overnight at 4°C

• Wash 4-5 times with lysis buffer

• Elute with 2X SDS sample buffer

Critical controls:

• Include IgG control immunoprecipitation

• Validate with reciprocal immunoprecipitation for protein-protein interaction studies

• Consider antibody orientation to avoid interference with interacting domains

How can I address weak or absent TRIM33 signal in Western blot experiments?

What are the most common challenges in TRIM33 immunostaining and how can they be overcome?

Challenge: High background staining

• Solution: Optimize blocking (5% BSA or normal serum)

• Increase washing steps (3x10 minutes)

• Decrease primary antibody concentration (1:100-1:500)

• Use specific antigen retrieval methods (TE buffer pH 9.0 preferred over citrate buffer pH 6.0)

Challenge: Low or no specific signal

• Solution: Verify TRIM33 expression in your cell/tissue type

• Optimize antigen retrieval (heat-induced epitope retrieval)

• Test different fixation methods

• Consider 48h timepoint for nuclear localization

Challenge: Non-specific staining

• Solution: Validate with TRIM33 knockdown/knockout controls

• Compare staining pattern with published literature

• Use monoclonal antibody for increased specificity

• Pre-adsorb antibody with immunizing peptide if available

How can TRIM33 antibodies be utilized to study its E3 ubiquitin ligase activity?

TRIM33's E3 ubiquitin ligase activity can be investigated through:

Co-immunoprecipitation coupled with ubiquitination assays:

• Immunoprecipitate target protein (e.g., SMAD4, c-Myc) using TRIM33 antibody

• Probe with anti-ubiquitin antibody to detect ubiquitinated forms

• Include proteasome inhibitor (MG132) treatment to stabilize ubiquitinated proteins

In vitro ubiquitination assays:

• Immunoprecipitate TRIM33 using validated antibody

• Add recombinant E1, E2 enzymes, ubiquitin, ATP, and substrate

• Detect ubiquitination by Western blot

Experimental design considerations:

• Include TRIM33 knockdown/knockout controls

• Compare wild-type vs. RING domain mutant TRIM33

• For c-Myc degradation studies, use cycloheximide chase assays with proteasome inhibitors

• Monitor protein half-life with or without TRIM33 overexpression

Recent studies show TRIM33 promotes c-Myc degradation in endometrial carcinoma cells, inhibiting glutamine metabolism and cancer cell proliferation .

What approaches can be used to study TRIM33's role in transcriptional regulation using antibodies?

Chromatin Immunoprecipitation (ChIP) methodologies:

• Cross-link protein-DNA complexes (1% formaldehyde, 10 minutes)

• Sonicate chromatin to 200-500 bp fragments

• Immunoprecipitate with TRIM33 antibody

• Analyze enriched DNA by qPCR or sequencing

Key target genes for ChIP-qPCR validation:

• Irf8 (dendritic cell differentiation)

• Bcl2l11 (cell survival regulation)

• Il17 and Il10 (Th17 cell function)

• KLK3, NKX3-1, FKBP5 (androgen receptor signaling)

Sequential ChIP (Re-ChIP) applications:

• Study TRIM33 co-occupancy with:

  • Androgen receptor (prostate cancer research)

  • ROR-γ and Smad2 (Th17 cell studies)

  • CTCF (chromatin architecture)

ChIP-seq analysis revealed >4000 TRIM33 binding sites enriched near genes involved in stem cell maintenance and mesoderm development, with nearly half overlapping CTCF insulator protein binding sites .

How can TRIM33 antibodies be applied to investigate its role in inflammatory responses?

TRIM33's role in inflammasome activation can be studied through:

Co-immunoprecipitation with inflammasome components:

• Immunoprecipitate using TRIM33 antibody from THP-1 derived macrophages

• Detect interaction with DHX33 (cytosolic dsRNA sensor)

• Validate interaction with NLRP3 inflammasome components

Functional assays:

• Measure IL-1β and IL-18 secretion in TRIM33 knockdown cells using ELISA

• Compare responses to cytosolic poly I:C, bacterial RNA, and viral RNA

Cell-specific expression studies:

• Compare TRIM33 expression and localization in:

  • THP-1 derived macrophages

  • Human primary monocyte-derived macrophages

  • Th17 cells (studying IL-17/IL-10 balance)

Research shows that TRIM33 knockdown reduces cytokine secretion in response to microbial RNA stimulation, suggesting its critical role in innate immune sensing .

What methodologies can be employed to investigate TRIM33's tumor suppressor functions?

Cell proliferation and migration assays:

• Establish TRIM33-overexpressing and TRIM33-knockdown cell lines

• Measure proliferation using CCK-8 or colony formation assays

• Assess migration/invasion using wound healing and Transwell assays

• Compare with appropriate controls

Metabolic function assessment:

• Measure glutamine uptake and intracellular glutamate production

• Analyze expression of metabolic enzymes (SLC1A5, GLS) by qPCR and Western blot

• Compare TRIM33 wildtype vs. mutant effects

In vivo tumor xenograft models:

• Inject TRIM33-modulated cells subcutaneously in nude mice

• Monitor tumor growth kinetics and final tumor weight

• Analyze tumor tissue for TRIM33, c-Myc, and metabolic markers

Recent studies in endometrial carcinoma demonstrate that TRIM33 overexpression inhibits proliferation, migration, and invasion in vitro, while also reducing tumor growth in vivo through c-Myc degradation and glutamine metabolism inhibition .

How are TRIM33 antibodies being applied in studies of cellular differentiation?

Hematopoietic differentiation studies:

• Track TRIM33 expression during differentiation stages

• Immunoprecipitate TRIM33 to identify stage-specific interaction partners

• Analyze chromatin occupancy changes during differentiation

Dendritic cell development applications:

• Monitor TRIM33-mediated regulation of Irf8 transcription

• Study CDK9 and Ser2-phosphorylated RNA polymerase II recruitment

• Investigate prevention of DC progenitor apoptosis through Bcl2l11 suppression

Cardiac development research:

• Examine TRIM33 expression in pre-cardiogenic mesoderm

• Study interaction with cardiac transcription factors

• Analyze chromatin remodeling during cardiac differentiation

Research demonstrates TRIM33 is crucial for dendritic cell differentiation from hematopoietic progenitors by promoting Irf8 transcription and preventing apoptosis through direct suppression of PU.1-mediated Bcl2l11 transcription .

What are the latest approaches to studying TRIM33 interactions with transcription factors?

Advanced protein interaction studies:

• RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins)

• Proximity labeling (BioID, TurboID) coupled with TRIM33 antibody validation

• FRET/BRET assays for live-cell interaction dynamics

Transcription factor complex analysis:

• Study TRIM33 interactions with:

  • Androgen Receptor in prostate cancer

  • ROR-γ and Smad2 in Th17 cells

  • PU.1 in dendritic cell development

  • Ctcf in chromatin architecture

Functional readouts:

• Gene expression analysis after perturbation of specific interactions

• Chromatin accessibility studies (ATAC-seq) with TRIM33 modulation

• Enhancer activity reporter assays

Research reveals TRIM33 is part of a core Androgen Receptor interactome across prostate cancer cell lines, with its loss reducing AR transcriptional output and altering prostate cancer cell phenotypes .

What new methodologies are being developed to study TRIM33's role in chromatin organization?

Advanced chromatin studies:

• HiChIP using TRIM33 antibodies to map long-range chromatin interactions

• CUT&RUN or CUT&Tag for higher resolution chromatin binding profiles

• SLIM-ChIP for low-input samples (rare cell populations)

Chromatin structure analysis:

• Investigate TRIM33's co-localization with CTCF at chromatin boundaries

• Analyze changes in TAD (Topologically Associated Domain) structure with TRIM33 perturbation

• Study enhancer-promoter interactions mediated by TRIM33

Integrated approaches:

• Combine TRIM33 ChIP-seq with RNA-seq and proteomics

• Correlate TRIM33 binding with histone modifications

• Map TRIM33-dependent chromatin accessibility changes

Research shows that nearly half of TRIM33 binding sites overlap with CTCF insulator protein binding sites, suggesting a role in chromatin architecture and gene regulation during development .